Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine.
A dengue subunit vaccine candidate was developed using a mammalian cell line continuously expressing subviral extracellular particles (EPs) of the New Guinea C (NGC) strain of dengue type 2 virus. The cell line, designated D cell line, maintained envelope (E) antigen production for at least 10 passages. The EPs contained an E protein biochemically and antigenically equivalent to authentic E produced by NGC-infected Vero cells. Two immunizations of BALB/c mice with purified EPs containing 100ng or 400ng of E induced moderate levels of neutralizing antibody and anamnestic neutralizing antibody responses were produced when these animals were challenged with dengue virus. The yield of E antigen from D cells was comparable to that from NGC-infected Vero cells. When D cells were transfected with the anti-apoptotic bcl-2 gene, the E antigen release increased approximately two-fold. These results indicate that D cell EPs are a promising non-infectious vaccine antigen for dengue.
Konishi
Eiji
E
Department of Health Sciences, Kobe University School of Medicine, 7-10-2 Tomogaoka, Suma-ku, 654-0142, Kobe, Japan. ekon@ams.kobe-u.ac.jp
Fujii
Atsuko
A
D000818:Animals; D001483:Base Sequence; D016466:CHO Cells; D006224:Cricetinae; D003716:Dengue Virus / Q000276:immunology*; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D008813:Mice, Inbred ICR; D008969:Molecular Sequence Data; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D014162:Transfection; D022223:Vaccines, Subunit / Q000096:biosynthesis / Q000276:immunology; D014614:Vaccines, Synthetic / Q000096:biosynthesis* / Q000276:immunology; D014759:Viral Envelope Proteins / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000096:biosynthesis* / Q000276:immunology
C051821:E-glycoprotein, Dengue virus type 2; D019253:Proto-Oncogene Proteins c-bcl-2; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines